

# 8,817 COVID Vaccine Injuries Reported to CDC Among Kids 5 to 11, as Study Shows Pfizer Vaccine Only 12% Effective in That Age Group

By [Megan Redshaw](#)

Global Research, March 07, 2022

[Children's Health Defense](#) 4 March 2022

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch\\_crg](#) and Twitter at [@crglobalization](#).

\*\*\*

*VAERS data released Friday by the Centers for Disease Control and Prevention included a total of 1,151,450 reports of adverse events from all age groups following COVID vaccines, including 24,827 deaths and 200,331 serious injuries between Dec. 14, 2020, and Feb. 25, 2022.*

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of [1,151,450 reports of adverse events](#) following COVID vaccines were submitted between Dec. 14, 2020, and Feb. 25, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of [24,827 reports of deaths](#) — an increase of 425 over the previous week — and [200,331 reports of serious injuries](#), including deaths, during the same time period — up 4,128 compared with the previous week.

Excluding “[foreign reports](#)” to VAERS, [774,373 adverse events](#), including [11,312 deaths](#) and [74,257 serious injuries](#), were reported in the U.S. between Dec. 14, 2020, and Feb. 25, 2022.

[Foreign reports](#) are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 11,312 U.S. [deaths reported](#) as of Feb. 25, 18% occurred within 24 hours of vaccination, 22% occurred within 48 hours of vaccination and 60% occurred in people who experienced an [onset of symptoms](#) within 48 hours of being vaccinated.

In the U.S., 552 million COVID vaccine doses had been administered as of Feb. 25, [including](#)

325 million doses of Pfizer, 208 million doses of Moderna and 18 million doses of Johnson & Johnson (J&J).

**National Vaccine Information Center**  
Your Health. Your Family. Your Choice.

## Search Results

From the 2/25/2022 release of VAERS data:

### Found 1,151,450 cases where Vaccine is COVID19

Government Disclaimer on use of this data

Table

Event Outcome	Count	Percent
Death	24,027	2.10%
Permanent Disability	45,015	3.90%
Office Visit	170,013	14.76%
Emergency Room	162	0.01%
Emergency Doctor/Room	121,389	10.54%
Hospitalized	125,438	10.89%
Hospitalized, Prolonged	345	0.00%
Recovered	582,635	50.60%
Birth Defect	658	0.00%
Life Threatening	20,345	1.76%
Not Serious	528,023	45.87%
<b>TOTAL</b>	<b>† 1,247,082</b>	<b>† 108.30%</b>

† Because some cases have multiple hospitalizations and symptoms, a single case can account for multiple entries in this table. This is the reason why the Total Count is greater than 1,151,450 (the number of cases found), and the Total Percentage is greater than 100.

Every Friday, [VAERS](#) publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only [1% of actual vaccine adverse events](#).

U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for 5- to 11-year-olds show:

[8,817 adverse events](#), including [200 rated as serious](#) and [4 reported deaths](#).

The most recent death involves an 8-year-old boy (VAERS I.D. [2109625](#)) from Mississippi who died 7 days after his second dose of Pfizer’s COVID vaccine when he was found blue and lifeless at home.

He was taken to the hospital with a full code in process. A pulse was detected several times, but the boy ultimately died in the ICU. It was reported to the doctor who filed the report that the boy died from [multisystem inflammatory syndrome](#). He did not have COVID.

- [17 reports](#) of myocarditis and pericarditis (heart inflammation).
- [32 reports](#) of blood clotting disorders.

U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for 12- to 17-year-olds show:

- [29,797 adverse events](#), including [1,714 rated as serious](#) and [39 reported deaths](#).

The most recent death involves a 13-year-old girl (VAERS I.D. [2115839](#)) from Wisconsin who was severely compromised and received two doses of Pfizer's COVID vaccine. Although the cause of death wasn't clear, she appeared to have significant health issues, respiratory distress and heart problems.

- [69 reports](#) of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to [Pfizer's vaccine](#).
- [648 reports](#) of myocarditis and pericarditis with [631 cases](#) attributed to Pfizer's vaccine.
- [159 reports](#) of blood clotting disorders, with all cases attributed to Pfizer.

U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for all age groups combined, show:

- 19% of deaths were related to cardiac disorders.
- 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The [average age](#) of death was 72.6.
- As of Feb. 25, [5,176 pregnant women](#) reported adverse events related to COVID vaccines, including 1,653 reports of [miscarriage or premature birth](#).
- Of the [3,587 cases of Bell's Palsy](#) reported, 51% were attributed to [Pfizer](#) vaccinations, 40% to [Moderna](#) and 8% to [J&J](#).
- 853 reports of [Guillain-Barré syndrome](#), with 41% of cases [attributed to Pfizer](#), 30% to [Moderna](#) and 28% to [J&J](#).
- [2,339 reports](#) of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- [1,621 reports](#) of myocardial infarction.
- [13,320 reports](#) of blood clotting disorders in the U.S. Of those, [5,946 reports](#) were attributed to Pfizer, [4,744 reports](#) to Moderna and [2,568 reports](#) to J&J.
- [4,060 cases](#) of myocarditis and pericarditis with [2,505 cases](#) attributed to Pfizer, [1,373 cases](#) to Moderna and [172 cases](#) to J&J's COVID vaccine.

Pfizer vaccine only 12% effective in kids 5 to 11, study says

A [study](#) released Monday showed the [effectiveness of Pfizer's COVID vaccine](#) in 5- to 11-year-olds was only 12% after a seven-week period of observation. Yet, the authors of the study still recommended the vaccine for that age group, stating it was protective against severe disease.

A study released Monday showed the effectiveness of Pfizer's COVID-19 vaccine in 5- to 11-year-olds was only 12% after a 7-week period of observation. According to New York Times, federal health officials knew about the findings since early February. <https://t.co/yW33Z7JePh>

— Robert F. Kennedy Jr (@RobertKennedyJr) [March 2, 2022](#)

They also proposed the recommended dose for 5- to 11-year-olds was too small, suggesting

a higher dose might solve the problem.

Some scientists at the CDC and FDA pushed for the data to be made public before an FDA meeting, scheduled for Feb. 15, to review Pfizer's application for Emergency Use Authorization of a three-dose regimen of its vaccine for infants and children 6 months to 5 years old — but the study's findings were only made public this week.

The FDA on Feb. 11 abruptly [postponed](#) the meeting to review Pfizer's application for infants and children under 5, stating Pfizer didn't have enough data on the efficiency of a third dose for that age group.

In an article [published](#) March 1, Dr. Madhava Setty, senior science editor at [The Defender](#), examined the data in the study and outlined two flaws in the authors' conclusions: 1) that the vaccines prevent severe disease in this age group, and 2) that increasing the dose might be appropriate.

Judge clears way for Pfizer whistleblower lawsuit

A [whistleblower lawsuit](#) alleging fraud during Pfizer's COVID vaccine trials is moving forward, after a district court judge [unsealed the complaint](#), including 400 pages of exhibits.

A whistleblower lawsuit alleging fraud during Pfizer's COVID vaccine trials is moving forward, after a district court judge unsealed the complaint, including 400 pages of exhibits. <https://t.co/ggNlMhN5Ov>

— Robert F. Kennedy Jr (@RobertKennedyJr) [March 2, 2022](#)

Brook Jackson in January 2021 [sued](#) Pfizer and two contractors that worked on its COVID vaccine clinical trials: [Ventavia Research Group](#) and [ICON PLC](#).

Jackson worked for Ventavia for a brief period in 2020, before being fired after she [filed a complaint](#) with the FDA over alleged indiscretions she observed during the vaccine trials.

She also gave [The BMJ](#) a cache of internal company documents, photos and recordings highlighting alleged wrongdoing by Ventavia.

Jackson filed the complaint in the U.S. District Court, Eastern District of Texas, Beaumont Division, under the [False Claims Act](#).

The lawsuit includes several charges of fraud and retaliation on the part of both Ventavia and Pfizer. The complaint remained under seal until Feb. 10, when U.S. District Court Judge Michael Truncale ordered it unsealed.

Husband of woman who died from J&J shot speaks out

The husband of an Oregon woman who died last year from a blood-clotting disorder — two weeks after receiving J&J's COVID vaccine — [spoke out publicly](#) this week about his wife's death.

U.S. health officials continue to say blood-clotting disorders like one that killed

52-year-old Monica Melkonian are two weeks after the J&J vaccine are rare — despite thousands of vaccine-induced blood-clotting events reported to CDC. <https://t.co/QqgggJY6tE>

— Robert F. Kennedy Jr (@RobertKennedyJr) [March 2, 2022](#)

Stan Thomas [told NBC News](#) he's fighting to ensure his wife's sacrifice is not forgotten.

Monica Melkonian, 52, received her J&J shot at a vaccination clinic on April 7, 2021 — the same day the CDC and FDA [temporarily paused](#) the vaccine to investigate reports of a rare blood-clotting disorder called [vaccine-induced thrombotic thrombocytopenia](#).

Melkonian's [most notable symptoms](#) included a persistent headache and pain behind her left eye before she experienced a seizure, stroke and ultimately died from the condition.

To date, the U.S. has [confirmed only nine deaths](#) due to VITT caused by the J&J shot and 54 cases of blood clotting conditions among J&J recipients, despite [thousands of cases](#) reported to VAERS.

Booster shots causing more injuries than expected in Israel

More Israelis are [experiencing injuries and reactions](#) following COVID booster shots than the country's passive reporting system shows, according to a survey conducted by the Israeli Ministry of Health (MOH).

The MOH [conducted](#) an active survey of booster shot recipients to collect data on adverse events associated with booster doses, then compared the survey data to the data available from the country's [passive reporting system](#).

Out of 4,000 people who [participated in the survey](#), results showed six of 2,049 respondents were admitted to the hospital following the booster shot, and a significant number of people reported worsening of their underlying health conditions.

Extrapolated to the millions of booster doses that have been administered, that's 270,000 hospitalizations per 92 million booster doses administered in the U.S. and 13,000 hospitalizations per 4.5 million booster shots administered in Israel.

The MOH survey also found reports of allergic reactions, menstrual irregularities, neurological injuries, injection-site reactions and general adverse events.

[Children's Health Defense](#) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following [these three steps](#).

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch\_crg and Twitter at @crglobalization. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

*Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.*

The original source of this article is [Children's Health Defense](#)  
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2022

---

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)